ABBV vs GILD: Side-by-Side Comparison
Compare Abbvie Inc (ABBV) and Gilead Sciences Inc (GILD) side by side: market cap USD 461.26B vs USD 162.98B, P/E 128.8 vs 17.9. Financials, growth and model signals on Bullrun.
| Metric | ABBV | GILD |
|---|---|---|
| Company | Abbvie Inc | Gilead Sciences Inc |
| Country / Exchange | United States · NYSE | United States · NASDAQ |
| Sector | Healthcare | Healthcare |
| Industry | Drug Manufacturers-General | Drug Manufacturers-General |
| Market cap | USD 461.26B | USD 162.98B |
| P/E ratio | 128.8 | 17.9 |
| Dividend yield | 2.58% | 2.45% |
| Valuation model | 66.8% overvalued | 9.2% undervalued |
| Revenue (FY2025) | USD 61.16B | USD 29.44B |
| Revenue growth YoY | +8.6% | +2.4% |
| Net income | USD 4.23B | USD 8.51B |
| Gross margin | 70.2% | 78.8% |
| Diluted EPS | 2.36 | 6.78 |